Key Points Hims & Hers operates a direct-to-consumer (DTC) telehealth platform for health and beauty, ED, hair loss, weight loss and non-urgent primary care needs. Hims & Hers reported a blowout Q1 2024 top and bottom line beat and raised the forecast for 2024. Hims & Hers announced they would start selling compounded GLP-1 (Semaglutide) for weight loss, a non-FDA-approved generic version of Ozempic and Wegovy. 5 stocks we like better than Hims & Hers Health Him & Hers Health Inc. NYSE: HIMS provides a dire ...